Brent L. Saunders - 22 Jun 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 22 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2022, 16:35:21 UTC
Prior SEC filing: 10 Jul 2024
Next SEC filing: 10 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Brian C. Stephenson, Attorney-in-Fact

Key filing fact

Brent L. Saunders filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 24 Jun 2022.

Key facts

This page summarizes Brent L. Saunders's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2022, 16:35.

Change

Previous filing in this sequence was filed on 10 Jul 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +104,921
Change %
Price: $0.000000
Shares after: 104,921
Date: 22 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 104,921
Exercise price: $8.45
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.